[Supplemental Announcement to 2022 Annual Report](index=1&type=section&id=Further%20Information%20Regarding%20the%20Annual%20Report%20for%20the%20Year%20Ended%20December%2031%2C%202022) This announcement supplements the 2022 annual report, detailing valuation methods for goodwill and accounts receivable impairment [Explanation of Valuation Methodologies Adopted](index=1&type=section&id=Reasons%20for%20Adopting%20Certain%20Valuation%20Methodologies) This section clarifies valuation methods and rationale for goodwill and accounts receivable impairment at Huaiyin Hospital [Goodwill Impairment: Discounted Cash Flow Model](index=1&type=section&id=Provision%20for%20Goodwill%20Impairment%20%E2%80%94%20Discounted%20Cash%20Flow%20Model) The company assessed Huaiyin Hospital's goodwill impairment using the discounted cash flow model, aligning with IAS 36 - The company assessed goodwill impairment for Huaiyin Hospital using the income approach (discounted cash flow model), which complies with **International Accounting Standard 36 – Impairment of Assets**[1](index=1&type=chunk) - This method was adopted because Huaiyin Hospital has a long financial history, providing a reliable basis for forecasting future performance, thus its recoverable amount is valued based on the present value of future cash flows[1](index=1&type=chunk)[2](index=2&type=chunk) [Accounts Receivable Provision: Expected Credit Loss Model](index=2&type=section&id=Accounts%20Receivable%20Provision%20%E2%80%94%20Expected%20Credit%20Loss%20Model) The company assessed Huaiyin Hospital's accounts receivable impairment using the IFRS 9 expected credit loss model - Accounts receivable impairment assessment follows the requirements of **International Financial Reporting Standard 9 – Financial Instruments**, utilizing the expected credit loss model[3](index=3&type=chunk) - The company applies a simplified approach to calculate expected credit losses, recognizing loss allowances based on lifetime expected credit losses at each reporting date without tracking credit risk changes[3](index=3&type=chunk) - The company has established a provision matrix to calculate losses, based on past credit loss experience and adjusted for debtor-specific forward-looking factors and economic conditions[3](index=3&type=chunk)

Business Model and Strategy - In 2022, the company adjusted its business model from focusing on operational efficiency to a sustainable development model known as "1+X," aiming to enhance medical technology and create more value for public health[16]. - The new development model is expected to lead to high-quality and sustainable growth, with a focus on creating reasonable surpluses[16]. - The company is committed to strengthening supply chain management and financial resources to support its new business strategy[16]. - The Group aims to complete the acquisition of Liaojian and Jiangneng projects and focus on merging quality state-owned hospitals[25]. - The Group's strategy includes expanding its business scale and establishing an efficient regional medical system[25]. - The Group plans to enhance profitability by improving medical service quality and operational efficiency while focusing on core functions such as strategy and finance[102]. Financial Performance - The annual medical business income totaled RMB8.336 billion, representing a slight increase of 0.8% year-on-year[19]. - The net profit attributable to the owners of the parent was RMB139 million, a year-on-year decrease of 66.7% due to operating losses and impairments from the acquisition of Huaiyin Hospital[19]. - The Group recorded a net profit of RMB159 million, a decrease of 62.6% year-on-year, primarily due to operating losses and exchange losses[30]. - The Group's net profit for the Reporting Period was RMB159 million, representing a year-on-year decrease of approximately 62.6%[81]. - The Group's income tax expenses amounted to RMB83 million during the Reporting Period, compared to a credit figure of RMB155 million in FY2021[80]. - The Group's total staff cost for FY2022 was approximately RMB 1.78 billion, an increase from RMB 1.18 billion in FY2021, attributed to the consolidation of certain hospitals[130]. Operational Metrics - The Group's annual outpatient visits increased by 2.1% year-on-year, while inpatient visits rose by 1.5%[19]. - The Group managed and operated 116 medical institutions across 8 provinces, with annual outpatient visits reaching approximately 15.27 million, a 41.6% increase from 2021[32]. - The total number of patients treated in 2022 was 15,266,657, reflecting a significant operational scale[42]. - The total number of operational beds was 11,115 with an overall utilization rate of 73%[42]. - The number of outpatient visits reached 15,266,657, while inpatient visits totaled 286,152, contributing to a total medical business revenue of RMB 8,336,458,000[42]. Revenue Breakdown - Revenue from self-owned hospitals was RMB 5,178,404,000, while IOT/OT hospitals generated RMB 430,637,000 in revenue[48]. - The revenue from the self-owned hospital segment increased by 0.9% year-on-year to approximately RMB 6.76 billion, while segment results decreased by 14.7% to approximately RMB 437 million[55]. - The revenue from outpatient visits was RMB 4,158,753,000, and inpatient visits generated RMB 4,021,749,000[48]. - The revenue from general healthcare services increased significantly by 108.3% to RMB 287 million[60]. Challenges and Impairments - The Group experienced a 10% increase in the number of patients treated compared to the previous year[41]. - The Group did not have any significant investments accounting for 5% or more of total assets as of December 31, 2022[89]. - For the fiscal year ended December 31, 2022, the Company recorded a provision for goodwill impairment of approximately RMB108 million due to the gradual loss of medical staff at Huaiyin Hospital, which significantly impacted its operations[73]. - Huaiyin Hospital's medical business revenue dropped by more than 50% year-on-year in 2022, resulting in an operating loss of approximately RMB76 million[73]. Employee and Talent Management - The total number of full-time employees increased to 9,668 as of December 31, 2022, from 8,454 in the previous year[130]. - Employee costs for the fiscal year 2022 amounted to approximately RMB 1.78 billion, up from RMB 1.18 billion in the fiscal year 2021, attributed to the consolidation of several hospitals during the year[133]. - The Group is committed to providing a safe and harassment-free working environment for employees, emphasizing workplace safety throughout the year[165]. - The Group has implemented a talent attraction program in response to the attrition of medical staff at Huaiyin Hospital to improve operations[73]. Environmental and Governance Policies - The Group has implemented environmental policies in compliance with PRC laws, with no material environmental claims or penalties reported during the year ended December 31, 2022[151]. - The Group has established a "Hazardous Substances Safety Management Plan" and a "Medical Waste Management System" for all hospitals to manage hazardous materials and medical waste[152]. - The Group's environmental, social, and governance report will be published alongside the annual report, detailing measures taken in these areas[160]. Dividends and Shareholder Information - The Group proposes a 2022 Final Dividend of 3.7 HK cents per Share, down from 12 HK cents in FY2021, totaling approximately HK$48 million[171]. - The Group's ability to pay dividends is contingent on its financial condition, operations, liquidity, and capital requirements[174]. - The company has no assurance that dividends will be paid in any particular amount for any given period[179].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 China Resources Medical Holdings Company Limited 華潤醫療控股有限公司 （於開曼群島註冊成立的有限責任公司） （股份代號：1515） 截至2022年12月31日止年度全年業績公告 | --- | --- | --- | |--------------------------------------------------|-----------|-----------| | | | | | 財務摘要 | 2022 年 | 2021 年 | | | | | | 收益（人民幣千元） | 5,620,461 | 4,447,477 | | 母公司擁有人應佔年度利潤（人民幣千元） | 138,974 | 417,915 | | 母公司普通股權益持有人應佔每股盈利（基本及攤薄） | | | | （人民幣） | 0.11 | 0.33 | | 建議分派之每股末期股息（港 ...

Financial Performance - The consolidated revenue for the reporting period amounted to RMB 2,850 million, a year-on-year increase of 60.8% from RMB 1,772 million[12]. - Net profit for the reporting period was RMB 215 million, slightly up from RMB 205 million in the corresponding period, indicating stable growth[12]. - Earnings per share remained unchanged at RMB 0.16 compared to the previous period[12]. - Total revenue from medical business for H1 2022 reached RMB 4,017,215, an increase from RMB 3,287,449 in the corresponding period[22]. - The net profit for H1 2022 was RMB 214,747, compared to a loss of RMB 5,740 in the corresponding period[22]. - The Group recorded a net profit of RMB 215 million, representing a year-on-year increase of 4.6%[41]. - Revenue for the six months ended June 30, 2022, was RMB 2,850,489, an increase of 61% compared to RMB 1,772,123 for the same period in 2021[118]. - Gross profit for the same period was RMB 524,266, representing a gross margin of approximately 18.4%[118]. - Profit before tax for the six months ended June 30, 2022, was RMB 254,175, a decrease of 5.9% from RMB 270,142 in the prior year[118]. - Comprehensive income for the period was RMB 214,747, compared to RMB 205,325 for the same period in 2021, indicating a slight increase[118]. Operational Metrics - The total number of outpatient visits increased by 66.1% to approximately 7.87 million, while inpatient visits rose by 11.4% to around 143,000[15]. - The number of operational beds increased to 11,369 with an overall utilization rate of 70.7%[19]. - Out-patient visits totaled 7,869,968, while in-patient visits were 142,877 for H1 2022[19]. - Total number of patients treated in H1 2022 was 7,869,968, with 4,941,511 being out-patients[19]. - The utilization rate of self-owned hospitals was 73.7%, while IOT/OT hospitals had a utilization rate of 51.6%[19]. Revenue Breakdown - Revenue from out-patient visits was RMB 1,996,751, and revenue from in-patient visits was RMB 1,971,362[22]. - Total revenue from medical business for self-owned hospitals increased by 7.7% year-on-year to approximately RMB 3.29 billion[29]. - The segment results for self-owned hospitals recorded a decrease of 1.7% to approximately RMB 265 million[31]. - IOT/OT hospitals segment achieved a 0.9% increase in medical business revenue, totaling RMB 729,766[34]. - IOT/OT hospitals segment results increased by 19.2% to RMB 58,843[34]. - Revenue from general healthcare services and hospital management services increased by 46.6% to RMB 121,373[32]. Expenses and Costs - The company reported administrative expenses of RMB 256,204, an increase from RMB 237,078 in the previous period[22]. - Total operating expenses of the headquarters decreased to approximately RMB 36 million, accounting for 12.4% of total administrative expenses[35]. - Staff costs for the reporting period were approximately RMB 836 million, a significant increase from RMB 471 million in the corresponding period[63]. - Selling and distribution expenses were RMB 8,779, while administrative expenses totaled RMB 292,473, indicating an increase in operational costs[118]. - The Group's profit before tax for the six months ended 30 June 2022 was significantly impacted by a cost of inventories sold amounting to RMB 1,476,492, an increase of 59.7% compared to RMB 924,993 in 2021[198]. Assets and Liabilities - The total assets as of June 30, 2022, were reported at RMB 5,000,000, compared to RMB 4,500,000 as of December 31, 2021, showing a growth in asset base[119]. - Total non-current assets increased to RMB 6,708,546, up from RMB 6,543,020, representing a growth of approximately 2.52%[120]. - Current assets rose to RMB 4,154,816, compared to RMB 3,924,582, reflecting an increase of about 5.86%[120]. - Total non-current liabilities surged to RMB 1,123,016, compared to RMB 177,423, indicating a dramatic rise[122]. - Total liabilities as of June 30, 2022, amounted to RMB 3,621,157, with interest-bearing bank borrowings at RMB 1,646,624[178]. Strategic Initiatives - The Group's strategic expansion includes the consolidation of additional medical institutions into its operations, enhancing its market presence[13]. - Future plans include enhancing the "RUNXIN" patient service system and modernizing hospital operations to improve service quality[53]. - The Group aims to improve operational efficiency and medical service quality through policy research on medical insurance payment reform and timely measures[55]. - The Group plans to seize merger and acquisition opportunities during the state-owned hospital reform period to accelerate growth[55]. - The Group recognizes the importance of maintaining relationships with patients and partners for sustainable development[62]. Governance and Compliance - The Company confirmed compliance with all material code provisions of the Corporate Governance Code during the reporting period[71]. - The risk management and internal control systems are designed to protect the Group's assets and ensure compliance with relevant laws and regulations[74]. - The Board will continue to optimize risk management and internal control systems in line with business development[80]. - The Group has performed annual impairment reviews of sponsorship rights, service contracts, and goodwill, concluding no impairment was required as of June 30, 2022[85]. Shareholder Information - China Resources Company Limited holds 474,319,516 shares, representing approximately 36.58% of the total issued shares[104]. - Mitsubishi UFJ Financial Group, Inc. holds 77,645,666 shares, accounting for about 5.98% of the total issued shares[104]. - The Board did not recommend the payment of any interim dividend for the reporting period, consistent with the corresponding period[68]. - No share options were granted, exercised, cancelled, or lapsed during the reporting period, and there are no outstanding share options under the Share Option Scheme[89].

Financial Performance - The Group recorded a net profit attributable to the parent of RMB418 million, an increase of 34.8% year-on-year and 6.9% compared to 2019[15]. - Total medical business revenue was RMB8,272 million, representing a rise of 24.5% year-on-year and a 20.4% increase compared to 2019[15]. - The Group achieved a consolidated revenue of RMB 4,447 million for the year ended December 31, 2021, representing a 61.6% increase from RMB 2,751 million in 2020 and a 109.8% increase from RMB 2,115 million in 2019[31]. - The net profit for the Group was RMB 426 million in 2021, up 33.1% from RMB 320 million in 2020 and a slight increase of 6.2% from RMB 401 million in 2019[32]. - The Group recorded a net profit of RMB 426,000,000 in 2021, representing a year-on-year increase of approximately 33%[95]. - The Group's earnings per share increased to RMB 0.33 in 2021, up from RMB 0.25 in 2020 and RMB 0.31 in 2019[32]. Operational Metrics - In 2021, the number of outpatient visits to member hospitals increased by 39.9% year-on-year and by 22.8% compared to 2019[15]. - The number of inpatient visits grew by 28.3% year-on-year and by 11.7% compared to 2019[15]. - The outpatient volume of member hospitals increased by 39.9% year-on-year and by 22.8% compared to 2019, while inpatient volume grew by 28.3% year-on-year and by 11.7% compared to 2019[17]. - The annual number of inpatient visits was approximately 282,000, reflecting an increase of 28.3% compared to 2020[37]. - The Group's member hospitals have shown a consistent trend of increasing operational metrics, indicating a positive outlook for future performance[40]. Strategic Initiatives - The company aims to be a leading healthcare group in China and a pioneer in the reform of state-owned medical institutions as part of its 14th Five-Year strategic plan[13]. - The Group aims to establish regional leading hospital clusters and academic specialty hospital clusters during the 14th Five-Year Plan, focusing on organic growth and external expansion[25]. - The Group plans to enhance medical technology, quality, and service capabilities to achieve high-quality growth and boost commercial value through group management and efficiency improvements[26]. - The company expressed gratitude to shareholders, staff, and frontline medical workers for their support during the pandemic[14]. Acquisitions and Consolidations - The Group consolidated the financial statements of Guangdong 999 Brain Hospital and Xukuang Hospital starting from August 2021, enhancing the reflection of business performance in financial statements[24]. - The acquisition of Huaiyin Hospital, a Grade II comprehensive for-profit hospital, was completed in June 2021, further expanding the Group's presence in the Yangtze River Delta region[20]. - The Group completed the acquisition of Huaiyin Hospital, which has been consolidated into the Group's financial statements since June 2021[38]. - The acquisitions of Jinan Zhongqi Hospital and Huaiyin Hospital contributed to the revenue growth in the self-owned hospitals segment[76]. Employee and Operational Management - As of December 31, 2021, the Group had a total of 8,454 full-time employees, an increase from 4,903 employees as of December 31, 2020[133]. - For FY2021, the staff cost was approximately RMB 1.18 billion, up from RMB 685 million in FY2020, primarily due to the acquisition and consolidation of certain hospitals[133]. - The Group has taken measures to attract, train, and retain qualified medical personnel to mitigate talent risk[130]. - The Group emphasizes the importance of relationships with patients and partners for sustainable business development[130]. Financial Position and Investments - As of December 31, 2021, the Group's consolidated bank balances and cash amounted to approximately RMB 3.23 billion, an increase from RMB 3.09 billion as of December 31, 2020[115]. - The Group's interest-bearing bank borrowings totaled approximately RMB 1.65 billion as of December 31, 2021, compared to approximately RMB 684 million as of December 31, 2020, indicating a significant increase[116]. - The Group's gearing ratio was 15.9% as of December 31, 2021, up from 7.6% as of December 31, 2020, reflecting increased leverage[117]. - The Group's investment in joint ventures and associates contributed a profit of RMB 83,553,000 during the reporting period[68]. Corporate Social Responsibility and Compliance - The Group has implemented strict environmental policies and complied with all relevant PRC laws regarding environmental protection during the year[151]. - The Group has developed various safety management plans, including the "Hazardous Substances Safety Management Plan" and "Medical Waste Management System" to ensure compliance with environmental regulations[152]. - The Group considers its employees as key to sustainable business growth and maintains a high standard of health and safety measures[165]. - The Group emphasizes a commitment to employee safety and equal opportunities, integrating these principles into its corporate responsibility policies[168]. Dividend and Shareholder Information - The Group proposes a final dividend of 12 HK cents per share for FY2021, an increase from 8.82 HK cents in FY2020, totaling approximately HK$156 million[171][175]. - The Group's ability to pay dividends is subject to its financial condition, operations, liquidity, and capital requirements[174][177]. - As of December 31, 2021, the Company's share premium amounted to RMB5,785,472,000, down from RMB5,877,796,000 in 2020, available for distribution to shareholders[183][189].

Financial Performance - The consolidated revenue for the six months ended June 30, 2021, amounted to RMB 1,772 million, a 95.2% increase from RMB 907 million in the same period last year[8]. - Net profit for the period was RMB 205 million, up 86.4% from RMB 110 million in the same period last year[8]. - Earnings per share increased to RMB 0.16, compared to RMB 0.09 in the same period last year[8]. - The total revenue from medical business for the first half of 2021 was RMB 3,777.148 million, with RMB 1,138.886 million from consolidated hospitals, RMB 1,914.703 million from unconsolidated hospitals, and RMB 723.559 million from IOT/OT hospitals[18]. - The group reported a net profit of RMB 205.325 million for the first half of 2021, with administrative expenses amounting to RMB 127.506 million[18]. - The financial results demonstrate a robust growth trajectory in the medical business, highlighting the effectiveness of the group’s expansion strategies[18]. - The effective control of the COVID-19 epidemic has led to a satisfactory recovery of operations and growth in revenue across the Group's member medical institutions[25]. - The Group recorded a net profit of RMB 205 million, representing an increase of 86.3% year-on-year[42]. - The company reported a significant increase in other income, which rose to RMB 54,697 from RMB 38,779, indicating improved operational efficiency[126]. - The company reported a fair value loss on financial assets at FVTPL of RMB 21,876,000, impacting overall profitability[167]. Operational Metrics - The overall number of out-patients and in-patients increased by 50.5% and 36.8%, respectively[8]. - The group operated 11,097 beds with an overall bed utilization rate of 71.6% during the first half of 2021, accommodating 128,270 inpatients[14][18]. - The revenue from outpatient visits was RMB 1,784.523 million, while inpatient visits generated RMB 1,928.301 million in revenue during the same period[18]. - The group’s outpatient and inpatient visit numbers reflect a significant operational scale, indicating strong demand for healthcare services[12][13]. - The segment results for unconsolidated hospitals showed a profit of RMB 154,745,000, indicating healthy operational performance[167]. Acquisitions and Expansions - On March 28, 2021, the company agreed to acquire approximately 99.19% of Huaiyin Hospital for a consideration of approximately RMB 880 million[9]. - The acquisition of Huaiyin Hospital was completed on June 17, 2021, and its financial statements have been consolidated into the Group[9]. - Jianghua Management Limited acquired 99.19% of Sinophi China Hospitals Limited for approximately RMB 880 million, completing the acquisition on June 17, 2021[11]. - The acquisition of Huaiyin Hospital indirectly increased the group’s operational capacity, as the hospital has approximately 1,190 open beds[11]. - The Group aims to enhance its core medical services and develop six discipline clusters, including cardiovascular and oncology, to strengthen its brand in these areas[55][57]. Financial Position - As of June 30, 2021, the group managed a total of 123 medical institutions across 8 provinces and cities in China, with approximately 4.739 million outpatient visits and 128,000 inpatient visits during the reporting period[12][13]. - As of June 30, 2021, the Group's consolidated bank balances and cash amounted to approximately RMB 2.49 billion, down from approximately RMB 3.09 billion as of December 31, 2020[60]. - The Group's gearing ratio as of June 30, 2021, was 16.3%, an increase from 7.6% as of December 31, 2020[61]. - Total non-current assets as of June 30, 2021, amounted to RMB 6,519,806, an increase from RMB 4,816,301 as of December 31, 2020[130]. - Total current assets were RMB 3,806,706, down from RMB 4,146,892 at the end of 2020, indicating a decrease in liquidity[130]. - Net current assets decreased to RMB 566,964 from RMB 1,939,706, highlighting a potential liquidity concern[130]. - Total liabilities were reported at RMB 3,705,924,000, including interest-bearing bank borrowings of RMB 1,663,511,000[177]. Staff and Management - As of June 30, 2021, the Group had a total of 6,097 full-time employees, an increase from 4,903 employees as of December 31, 2020, primarily due to the acquisition of Huaiyin Hospital[67]. - Staff costs for the six months ended June 30, 2021, were approximately RMB 471 million, compared to RMB 205 million for the same period in 2020, reflecting a significant increase[67]. - The Board did not recommend the payment of any interim dividend for the six months ended June 30, 2021, consistent with the previous year[71]. Risk Management and Compliance - The Group's risk management and internal control systems are designed to protect assets and ensure compliance with laws and regulations[82]. - The Audit Committee reviewed the unaudited consolidated interim results and confirmed compliance with relevant accounting standards and legal requirements[77]. - The Company confirmed compliance with all material code provisions of the Corporate Governance Code during the reporting period[75]. Future Strategies - The Group plans to improve operational efficiency and reduce costs while expanding existing hospitals and pursuing mergers and acquisitions[55][57]. - Future strategies include enhancing operational efficiencies and exploring potential acquisitions to strengthen market position[170].

Financial Performance - In 2020, the total medical business revenue was RMB 6.644 billion, representing a slight decrease of 3.3% from the previous year[13]. - The consolidated net profit for 2020 was RMB 320 million, a 20% decrease from the previous year[13]. - The consolidated revenue for the year ended December 31, 2020, was RMB 2.751 billion, an increase from RMB 2.115 billion in FY2019, primarily due to the acquisition of Jinan Zhong Qi Hospital[25]. - Net profit for the period was RMB 320 million, down from RMB 401 million in FY2019, with earnings per share decreasing to RMB 0.25 from RMB 0.31, mainly due to a drop in hospital visits caused by the COVID-19 epidemic[25]. - The total revenue from medical business of member hospitals was approximately RMB 6.644 billion, representing a year-over-year decrease of 3.3% due to the impact of the COVID-19 epidemic[26]. - The Group recorded a net profit of RMB320 million, representing a year-on-year decrease of approximately 20.0% due to the impact of the COVID-19 epidemic[78]. - The total revenue from goods and services for the reporting period was approximately RMB2.751 billion, with a cost of sales amounting to RMB2.114 billion, resulting in a gross profit of RMB636 million[48]. - The segment results for 2020 amounted to approximately RMB452 million, representing a decrease of about 31.7% compared to the previous year, primarily due to a 12.9% decrease in inpatient visits and a 12.2% decrease in outpatient visits attributed to the COVID-19 epidemic[51][52]. - Revenue from the consolidated hospital segment increased by 127.9% year-on-year to approximately RMB1.644 billion, with segment results rising by 2.9% to approximately RMB128 million, driven by the recovery of operations in the Huaikuang Hospital Group and Jinan Zhong Qi Hospital[55]. - The unconsolidated hospital segment experienced a medical business revenue decline of 32.6% year-on-year to approximately RMB 2.344 billion, with a profit decrease of 45.7% to approximately RMB 131 million[63]. Operational Developments - The company completed the acquisition of Jinan Zhong Qi Hospital in early 2020 and acquired the remaining equity interest in the second half of the year[16]. - The company formed a neurology specialty cluster centered around Sanjiu Brain Hospital, consolidating medical resources in Guangdong and Guangxi[16]. - The company focused on enhancing six main discipline clusters: orthopedic, encephalopathy, rehabilitation, oncology, cardiology, and gastroenterology through new talents and technologies[16]. - Business operations began to significantly recover from May 2020, with a rebound in patient numbers observed[32]. - The management team implemented a phased resumption of operations, with all member hospitals returning to normal operations by the end of March 2020[32]. - The Group completed the acquisition of Jinan Zhong Qi Hospital and consolidated certain other hospitals, with the financial statements of Jinan Zhong Qi Hospital being included in the Group's financials since April 2020[33]. - The Group has consolidated additional hospitals into its financial results, enhancing its operational capacity and market presence[54][56]. - The Group's financial statements have included Run Neng Hospitals since June 2020 following similar constitutional amendments[34]. - The Group has established a strong supply chain management system to ensure sufficient medical supplies during the COVID-19 epidemic[30]. Human Resources - As of December 31, 2020, the Group had a total of 4,903 full-time employees, a significant increase from 1,178 employees as of December 31, 2019[124]. - For FY2020, the staff cost was approximately RMB 685 million, up from RMB 355 million in FY2019, primarily due to acquisitions and consolidations of hospitals[124]. - The Group is actively working to attract and retain qualified medical staff to mitigate the risk of talent shortage[109][114]. Strategic Focus - The company aims to focus on business development in key regions including Beijing-Tianjin-Hebei, the Yangtze River Delta, and the Greater Bay Area[19]. - The company plans to strengthen key specialties and accelerate the transformation of specialty clusters to enhance its clinical brand and service quality[21]. - Future plans include focusing on specialty chain hospitals and general hospitals, with a geographical focus on key regions in China[95]. - The Group aims to cultivate six discipline clusters in cardiovascular, encephalopathy, orthopedics, rehabilitation, gastroenterology, and oncology to strengthen competitive advantages[95]. Financial Management - The Group's liquidity and financing strategy emphasizes maintaining a solid financial position through cash generated from operations and bank facilities[96]. - As of December 31, 2020, the Group's consolidated bank balances and cash amounted to approximately RMB 3.09 billion, an increase from approximately RMB 2.276 billion as of December 31, 2019[100][104]. - The Group has obtained offshore revolving term loan facilities totaling HK$3.8 billion, with HK$3 billion having no fixed term and HK$800 million being a one-year term[101][105]. - Interest-bearing bank borrowings as of December 31, 2020, were HK$799 million and RMB 12 million, equivalent to approximately RMB 684 million, compared to HK$646 million (approximately RMB 578 million) as of December 31, 2019[101][105]. - The Group's gearing ratio was 7.6% as of December 31, 2020, slightly up from 7.3% as of December 31, 2019[102][106]. - The Group's unutilized bank facilities amounted to HK$3.001 billion and RMB 3 million, equivalent to approximately RMB 2.529 billion as of December 31, 2020[101][105]. Corporate Governance and Compliance - The Group has complied with all relevant PRC laws and regulations regarding environmental protection during the year ended December 31, 2020[144]. - The Group has implemented various safety management plans, including those for hazardous substances and medical waste, to ensure compliance with environmental laws[145]. - The Group emphasizes the importance of employee welfare, providing a safe working environment and equal opportunities for career development[158]. - The Group's sustainability report will be published within three months after the annual report, detailing environmental, social, and governance measures[149]. - The Group maintains a fair and effective performance appraisal system and incentive bonus schemes to motivate employees[158]. - The Group is committed to balancing the interests of various stakeholders, including substantial shareholders, employees, and the community[151]. Dividends and Shareholder Returns - The Group proposes a final dividend of 8.82 HK cents per share for FY2020, down from 10 HK cents in FY2019, totaling approximately HK$114 million[164]. - The Group's ability to pay dividends is subject to its financial condition, operations, liquidity, and capital requirements[167]. - The dividend policy will be reviewed periodically, with no assurance of specific amounts being paid in any given period[172].

Financial Performance - The consolidated revenue for the six months ended June 30, 2020, was RMB 907 million, a decrease of 6.0% compared to RMB 965 million in the same period last year[11]. - Net profit for the period was RMB 110 million, down 41.6% from RMB 189 million in the previous year, with earnings per share of RMB 0.09 compared to RMB 0.15[11]. - The total revenue from medical business of member hospitals decreased by 18.0% to approximately RMB 2.702 billion during the reporting period[12]. - In H1 2020, the total number of operational beds was 10,872, with an overall bed utilization rate of 57.1%[29]. - Revenue from medical business in H1 2020 amounted to RMB 2,702,450,000, with outpatient revenue at RMB 1,313,679,000 and inpatient revenue at RMB 1,356,412,000[33]. - The Group's net profit was RMB 110 million, reflecting a year-on-year decrease of 41.5%[60]. - Profit before tax decreased to RMB 156,191,000, representing a decline of 38.5% from RMB 253,941,000 in the previous year[143]. - Comprehensive income for the period was RMB 110,220,000, down 41.5% from RMB 188,524,000 in 2019[143]. - The Group's consolidated hospitals included Jinan Zhong Qi Hospital from April 2020, contributing to the overall financial performance[34]. - The overall medical business revenue of the unconsolidated hospital segment decreased by 32.3% year-on-year to approximately RMB1.174 billion, with segment profit decreasing by 54.9% to approximately RMB47.84 million, also impacted by COVID-19[45]. Operational Impact of COVID-19 - The company implemented strict COVID-19 prevention measures, including the formation of an emergency team led by the CEO to manage the epidemic response[13]. - No medical staff from member hospitals have been infected by COVID-19 as of the date of the report[16]. - The management emphasized the importance of employee health and well-being, implementing measures to support their physical and psychological health[16]. - During the reporting period, the total number of inpatient and outpatient visits to member hospitals decreased by 26.3% and 23.7% respectively due to the epidemic[20]. - The emergency supply team established by CR Medical ensured sufficient supply of prevention and control materials to member institutes during the tight supply situation[18]. - The number of patients at member hospitals rebounded significantly in May 2020, indicating a recovery in business operations[20]. - The company has implemented measures to address the impact of COVID-19, which affected the overall performance and profitability of member hospitals during the reporting period[38]. Employee and Management Measures - The management team and all medical staff postponed their leave and remained on duty during the epidemic[20]. - The Group had a total of 4,843 full-time employees as of June 30, 2020, a significant increase from 1,178 employees as of December 31, 2019[81]. - Employee costs for the six months ended June 30, 2020, amounted to approximately RMB 205 million, compared to RMB 162 million for the same period in 2019, reflecting a year-on-year increase of 26.5%[84]. - The Group's employee count in non-consolidated hospitals was 4,300 as of June 30, 2020, down from 7,422 as of December 31, 2019[84]. Financial Position and Assets - As of June 30, 2020, the Group's consolidated bank balances and cash amounted to approximately RMB2.905 billion, an increase from RMB2.276 billion as of December 31, 2019[71]. - Total non-current assets as of June 30, 2020, amounted to RMB 4,658,006,000, a slight decrease from RMB 4,675,772,000 at the end of 2019[145]. - Total current assets increased to RMB 3,908,106,000 from RMB 3,198,209,000 at the end of 2019, reflecting a growth of 22.2%[145]. - Total liabilities were recorded at RMB 2,342,153,000, with segment liabilities from consolidated hospitals at RMB 821,599,000[190]. - The company reported financial assets at fair value through profit or loss (FVTPL) totaling RMB 1,585,187,000, indicating a strong investment position[190]. Strategic Plans and Future Outlook - The Group aims to complete the restructuring of Jing Mei Hospital in the third quarter of 2020[70]. - Future plans include capital requirements for the proposed reform of Jing Mei Hospital Group and further investments in Jinan Zhong Qi Hospital[67]. - The Group plans to advance the specialized reform of two hospitals in South China within the year[70]. - The company is focusing on expanding its GPO business and enhancing its hospital management services to drive future growth[180]. - Future outlook remains cautious due to market uncertainties, but strategic expansions are planned[199]. Governance and Compliance - The Board confirmed compliance with all material code provisions of the Corporate Governance Code during the review period[89][90]. - The Board has reviewed the efficiency of the Group's risk management and internal control systems across various aspects, including financial and operational areas[95]. - The Group's risk management and internal control systems are designed to protect assets and ensure compliance with relevant laws and regulations[93][94]. - There were no significant contractual obligations that would materially impact the Group's financial position or operations as of June 30, 2020[85]. Segment Performance - The Group is organized into four reportable operating segments: Consolidated hospitals, Unconsolidated hospitals, IOT/OT hospitals, and Others, for management purposes[170]. - Segment performance is evaluated based on reportable segment profit/loss, which is adjusted profit/loss before tax, excluding certain items like share of profits and losses of joint ventures[170]. - Consolidated segment results totaled RMB 290,213,000 for the period, with contributions from consolidated hospitals at RMB 54,741,000, unconsolidated hospitals at RMB 106,088,000, and IOT/OT hospitals at RMB 121,831,000[186].

Financial Performance - In 2019, the annual outpatient volume of member hospitals increased by 6.8% year-on-year, while inpatient volume rose by 1.7%[14]. - The medical service revenue of member hospitals reached RMB 6.87 billion, representing a 2.8% increase compared to 2018[14]. - Excluding the impacts of Yanhua Hospital, the medical revenue of in-network hospitals recorded a year-on-year increase of over 10%[14]. - The Group's net profit for 2019 was RMB 401 million, reflecting a year-on-year decrease of only 8.9%[14]. - After excluding Yanhua Hospital's after-tax contribution, the Group's net profit was RMB 397 million, indicating a year-on-year increase of 10.5%[14]. - Total revenue from medical business of in-network hospitals grew by 2.8% to approximately RMB 6.869 billion[34]. - The average outpatient spending per visit decreased by 4.5%, while average inpatient spending per visit increased by 1.5%[34]. - The profit margin for the for-profit hospital segment increased to 17.3% from 15.4% in the prior year, with segment results reaching approximately RMB 125 million, a 16.7% increase year-on-year[57]. - The medical business revenue from for-profit hospitals was RMB 721 million, which was included in the Group's consolidated revenue, while the revenue from sponsored and IOT/OT hospitals totaled approximately RMB 6.148 billion, not included in the consolidated revenue[51]. - The Group's net profit for 2019 was approximately RMB 401 million, representing a Year-on-Year decrease of 8.9%[79]. Operational Developments - The company launched the "RUNXIN" patient service system to improve service quality during the reporting period[17]. - Guangzhou 999 Brain Hospital obtained an Internet hospital license in October 2019, enabling online medical consultations[17]. - The company implemented a four-tier system to combat COVID-19, enhancing the support for medical institutions[13]. - The strategic goals focused on leading scale, improving capabilities, and emphasizing innovation[17]. - The company created its own info-tech platform and tailored a centralized "Medical + Internet" strategy[17]. - The group managed and operated 107 medical institutions across 10 provinces and cities in China as of December 31, 2019[36]. - The group achieved a bed utilization rate of 73.0% across its medical institutions[43]. - For-profit hospitals had a bed utilization rate of 88.4% with revenue from outpatient and inpatient visits totaling RMB 721.055 million[43]. - The Group has begun providing hospital management services to Run Neng Hospitals during the reporting period[40]. - Tai'an City Hospital commenced operations in April 2020 under a 20-year management agreement[40]. Strategic Initiatives - The company aims to strengthen specialists and branding as a strategic goal for 2020, focusing on high-quality for-profit general hospitals and SOE owned hospitals[22]. - The company has initiated the development of specialty services through industry research and strategic analysis[20]. - The Group plans to enhance its "RUNXIN" patient service system and launch innovative "Medical + Internet" products in 2020[98]. - The focus for 2020 includes strengthening specialties and establishing the brand, particularly in six key disciplines: orthopedics, encephalopathy, rehabilitation, oncology, cardiology, and gastroenterology[98]. Financial Position and Investments - As of December 31, 2019, the Group's consolidated bank balances and cash amounted to approximately RMB 2.276 billion, an increase from approximately RMB 1.9 billion in 2018[100]. - The Group had interest-bearing bank borrowings of HK$646 million (approximately RMB 578 million) as of December 31, 2019[100]. - The unutilized bank credit facilities amounted to HK$ 2.354 billion (approximately RMB 2.109 billion) as of December 31, 2019[104]. - The Group's gearing ratio was 7.3% as of December 31, 2019, up from 6.7% in 2018[105]. - The Group confirmed no concrete plans for significant investments or acquisitions outside of ordinary business operations as of the report date[92]. - The fair value of the investment in UMP Healthcare Holdings was approximately RMB 113 million as of December 31, 2019[93]. Compliance and Governance - The Group has complied with all relevant PRC environmental laws and regulations during the year ended December 31, 2019, with no reported environmental claims or penalties[134]. - The Group has implemented the "Hazardous Substances Safety Management Plan" and "Medical Waste Management System" across all hospitals to manage hazardous substances and medical waste effectively[135]. - The Group has established a "Utilities Safety Management Plan" and "Safety and Protection Management Plan" to ensure safety in hospital operations[139]. - The Group prioritizes employee safety and has maintained high health and safety standards throughout its activities, supported by a performance appraisal system and incentive bonus schemes[149]. - The Group adheres to strict ethical and professional standards in transactions with suppliers and contractors, conducting annual performance reviews[153]. - The Group's procurement policy aims to ensure compliance with local labor, health, safety, and environmental regulations[153]. Human Resources - The total staff cost for FY2019 was approximately RMB 355 million, an increase from RMB 316 million in FY2018[118]. - The Group had a total of 1,178 full-time employees as of December 31, 2019, compared to 1,120 employees as of December 31, 2018[118]. Dividends and Shareholder Information - The Group proposes a final dividend of 10 HK cents per share for FY2019, down from 12 HK cents in FY2018, totaling approximately HK$130 million[155][159]. - The Group's ability to pay dividends is contingent upon its financial condition, operations, liquidity, and capital requirements[158][161]. - The dividend policy will be reviewed periodically, with no assurance of specific amounts being paid in any given period[163][170]. Subsequent Events - Significant events affecting the Group since the end of the reporting period are detailed in the "Subsequent Events" section of the annual report[133].

Financial Performance - The consolidated revenue for the six months ended June 30, 2019, amounted to RMB 965 million, representing a year-on-year increase of 5.3% from RMB 916 million in the same period last year[16]. - Net profit for the period was RMB 189 million, a decrease from RMB 207 million in the same period last year[16]. - Earnings per share for the Company were RMB 0.15, down from RMB 0.16 in the same period last year[16]. - The group achieved a total revenue of RMB 965 million for the six months ended June 30, 2019, representing a year-on-year growth of 5.3% compared to RMB 916 million in the same period last year[17]. - Net profit for the same period was RMB 189 million, down from RMB 207 million year-on-year, resulting in earnings per share of RMB 0.15, compared to RMB 0.16 in the previous year[17]. - Total comprehensive income for the period was RMB 188,524,000, down from RMB 210,343,000, representing a decline of approximately 10.4%[140]. - The Group's net profit for the first half of 2019 was RMB 189 million, representing a year-on-year decrease of 8.8%[59]. - Excluding the profit contribution from Yan Hua Hospital, the Group's net profit increased by 15.8% year-on-year to RMB 185 million[59]. Operational Metrics - The Group managed and operated a total of 110 medical institutions across 10 provinces and cities in China as of June 30, 2019[16]. - Outpatient visits increased by 7.5% to 4,129,212 times, while inpatient visits rose by 5.6% to 127,198 times[16]. - The number of outpatient visits increased by 7.5% to 4,129,212, while inpatient visits grew by 5.6% to 127,198[17]. - The utilization rate of beds in for-profit hospitals was 85.7%, while for sponsored hospitals it was 78.6%[23]. - Revenue from outpatient visits in for-profit hospitals was RMB 189 million, and inpatient revenue was RMB 134 million[23]. Revenue Breakdown - Total revenue from medical business of in-network hospitals grew by 3.90% to approximately RMB 3.298 billion[16]. - Total revenue from medical business increased by 3.9% to approximately RMB 3.298 billion[17]. - The medical business revenue from for-profit hospitals was RMB 327 million, while the total medical business revenue from sponsored and IOT/OT hospitals was approximately RMB 2.971 billion, which was not included in the consolidated revenue[29]. - Medical business revenue from sponsored hospitals increased by 33.0% year-on-year to RMB 1.734 billion, driven by newly acquired Run Neng Hospitals contributing approximately RMB 197 million[39]. - IOT/OT hospitals segment medical business revenue decreased by 19.6% to RMB 1.237 billion, but increased by 8.3% year-on-year when excluding the impact of the Yan Hua Hospital Group[44]. Expenses and Costs - The average outpatient spending per visit decreased by 6.4%, while average inpatient spending per visit remained largely unchanged[16]. - The administrative expenses for the first half of 2019 amounted to RMB 6.97 million, with other expenses totaling RMB 54.14 million[28]. - The total operating expenses for the headquarters were RMB 52.87 million, impacting the overall profitability[28]. - The finance costs for the first half of 2019 were RMB 7.45 million, affecting the net profit[28]. - Total finance costs rose to approximately RMB 7 million, primarily due to increased bank loan balances and interest rates[52]. - Interest paid increased to RMB 4,971,000 from RMB 1,558,000 in the prior year, indicating higher financing costs[160]. Cash Flow and Assets - Cash generated from operations was RMB 110,535,000, a significant decrease from RMB 213,419,000 in the previous year, reflecting a decline of approximately 48.2%[156]. - Current assets increased to RMB 2,840,191,000 from RMB 2,533,227,000, reflecting a growth of approximately 12.1%[142]. - Net current assets improved to RMB 1,563,353,000, up from RMB 1,255,954,000, indicating an increase of about 24.4%[142]. - Cash and cash equivalents at the end of the period stood at RMB 1,555,455,000, up from RMB 1,149,810,000 at the end of the previous year[160]. Shareholder Information - The Board did not recommend the payment of any interim dividend for the six months ended June 30, 2019, consistent with the previous year[96]. - The interests of directors and chief executives in the company's shares included 1,500,000 shares held by Wu Ting Yuk, Anthony, representing approximately 0.12% of total shares[116]. - China Resources Company Limited held 466,824,016 shares, representing 36.00% of the total shares[122]. - Commonwealth Bank of Australia held 128,632,500 shares, representing 9.92% of the total shares[122]. Risk Management and Compliance - The risk management and internal control systems are designed to protect the Group's assets and ensure compliance with relevant laws and regulations[106]. - The Board performed a review of the efficiency of the Group's risk management and internal control systems during the six months ended June 30, 2019[108]. - The board believes that the current risk management and internal control systems adequately cover the existing business of the group and will continue to improve based on business development[110]. - The Group is exposed to fair value interest rate risk related to receivables from IOT Hospitals and loans to a sponsored hospital, and cash flow interest rate risk from floating interest-bearing bank balances[75]. Accounting Policies - The accounting policies for the interim condensed consolidated financial information for the six months ended June 30, 2019, are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended December 31, 2018, except for the adoption of new and revised IFRSs effective January 1, 2019[169]. - The adoption of IFRS 16 Leases did not have any significant financial effect on the Group's results of operation and financial position, except for certain amendments related to long-term interests in associates and joint ventures[172]. - The Group adopted IFRS 16 using a modified retrospective method with the date of initial application of January 1, 2019, and the comparative information for 2018 was not restated[175].